Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylprednisolone + platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Combined Military Hospital Rawalpindi
- Modality
- Small Molecules
- Administration
- Intratympanic
01
Overview
This investigational combination therapy consists of the synthetic corticosteroid methylprednisolone and autologous platelet-rich plasma (PRP), administered via intratympanic injection. Developed and evaluated at the Combined Military Hospital (CMH) Rawalpindi, the treatment is designed for patients suffering from sensorineural hearing loss (SNHL) and tinnitus of cochlear origin. Methylprednisolone provides potent anti-inflammatory effects to reduce cochlear stress, while the autologous PRP serves as a biologic medium rich in growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF). These factors are intended to promote tissue repair and regeneration within the inner ear structures, such as the cochlea, by enhancing local healing processes that are otherwise limited by the ear's end-artery blood supply.
- Other names
- IT-MP + PRPIntra-Tympanic Methylprednisolone-Platelet Rich PlasmaMethylprednisolone + PRP
02
Targets
GR (Glucocorticoid receptor)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR (VEGFR family)PDGFR (PDGFR family)
Beyond the preview
Go deeper on methylprednisolone + platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylprednisolone + platelet-rich plasma.